News

On 26 October 2016 the District Court of The Hague held Icos Corporation’s patent for a formulation of tadalafil invalid in proceedings initiated by Actelion Pharmaceutical Inc. In its reasoning, the Court applied the “try and see” test. Icos owns European Patent EP 1 200 092 (EP092) relating to a small-sized-particle formulation of the known

On 6 July 2016 the The Hague District Court handed down its decision in the final relief infringement proceedings that Novartis initiated against Alvogen and Focus Farma. The Court rejected Novartis’ claim based on infringement of its patent for patches containing rivastigmine, because the patent was invalid. Novartis AG is co-owner of EP 2 292

On 15 January 2016 the Provisions Judge of the The Hague District Court handed down his decision in interim relief proceedings in the case of Warner-Lambert Company LLC vs. The State (Ministry of Health, CBG), ordering CBG (the Dutch MEB) to replace the online versions of the full label SmPC and PIL for generic pregabalin

In its interlocutory judgement of 25 November 2015 in the case Sun Pharmaceutical Industries (Europe) B.V. v. Novartis et al.the District Court of The Hague ruled that Sun has not indirectly infringed Novartis’ second medical use patent EP 1 2 96 689 (EP ‘689) relating to the treatment of osteoporosis. With its judgment, the District

In his decision of 30 March 2016 in the matter Novartis AG v Teva Nederland B.V. et al., the Provisions Judge of the District Court in The Hague held that Novartis is entitled to a Paediatric Extension for Glivec® (imatinib), based on Supplementary Protection Certificate no. 300086. The Provisions Judge has provisionally prohibited Teva to